DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction

Exclusion Criteria

• •Cardiogenic shock (SBP \<90 mmHg with clinical signs of low output or patients requiring inotropic agents) at randomization;
• •Referred to surgery for coronary artery bypass grafting (CABG) or treatment of acute complications (e.g. ventricular septal rupture);
• •Any other form of diabetes than diabetes type 2
• •History of diabetic ketoacidosis (DKA); Known contra-indication to SGLT-2 inhibitors (hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption);
• •\>1 episode of severe hypoglycemia within the last 6 months under treatment with insulin or sulfonylurea;
• •Acute symptomatic urinary tract infection (UTI) or genital infection at the time of randomization;
• •Concomitant treatment (and/or within the 4 weeks prior to the baseline visit) with any SGLT-2 inhibitor (dapagliflozin, canagliflozin, empagliflozin)
• •Echocardiographic examination of insufficient quality to permit adequate analysis of the study end-points.
• •Impossibility to evaluate cardiac remodeling using TTE (e.g., pacemaker or defibrillator …);
• •Atrial fibrillation rhythm at randomization;
• •Life expectancy \<6 month;
• •Known pregnancy at time of randomization;
• •Breastfeeding women
• •Females of childbearing potential without adequate contraceptive methods (i.e. sterilization, intrauterine device, vasectomized partner; or medical history of hysterectomy)
• •Current participation in another interventional trial. Patients under guardianship or curatorship